Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CBFB | Q13951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546322 | 0.82 | KDM4C (0.39) | KDM4CMAPKAPK2GRM4ADRA2ASYK | |
| SCHEMBL21823771 | 0.77 | S1PR1 (0.40) | GRM4KDM4EHPGDCYP19A1CDC7 | |
| SCHEMBL29545665 | 0.69 | HSP90AA1 (0.44) | KMOSYK | |
| SCHEMBL12072711 | 0.67 | KIF11 (0.50) | GSK3BCYP19A1 | |
| SCHEMBL23416953 | 0.66 | NPSR1 (0.45) | KDM4CGPBAR1KDM4E | |
| SCHEMBL29797725 | 0.66 | NPSR1 (0.45) | KDM4CGPBAR1KDM4E | |
| SCHEMBL21823796 | 0.64 | CYP19A1 (0.45) | KDM4CGRM4KDM4ECYP19A1 | |
| SCHEMBL21823768 | 0.63 | CYP19A1 (0.44) | KDM4CKDM4EHPGDCYP19A1 | |
| SCHEMBL4659534 | 0.62 | GRM4 (0.49) | GRM4ADRA2AKDM4ECYP19A1 | |
| SCHEMBL21052300 | 0.61 | HDAC6 (0.48) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | KDM4C 825/4885MAPKAPK2 824/4885GRM4 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.